This area of our website is for healthcare professionals only

Please click below to declare your professional status:

YES, I am a healthcare professional  NO, I am not a healthcare professional

Complete research list

See the latest quality research around lipid conditions and their treatments


LDL cholesterol, triglycerides and cholesterol as risk factors for CVD

Ference, M., Kastelein, J., Ray, K et al (2019) Association of triglyceride lowering LPL variants and LDL-C lowering LDLR variants with risk of coronary heart disease. JAMA. 321. 4. 364-373.  Available at: Jamanetworkfullarticle

Ference, M., Ginsburg, H., Graham, I., Ray, K et al (2017) Low density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic and clinical studies.  A consensus statement from the European Atherosclerosis Society Pane.  European Heart Journal.  Available at:

Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. The Lancet.  Available at: 

Familial Chylomicronaemia Syndrome 

Stroes, E., Moulin, P., Parhofer, K et al (2017) Diagnostic algorithm for familial chylomicronemia syndrome. Atherosclerosis.  Supplement. 23. 1-7.  Full supplement available

Familial hypercholesterolaemia: PCCJ sponsored familial hypercholesterolaemia series

For free access to these articles, you can sign up to the PCCJ Plus Website at

Milne D (2013)  Its not just a high cholesterol, it can be an indicator of a genetic disorder. Prim Care Cardiovasc Journal.  6. pp122-124. 

Neely, R (2013).  The importance of early diagnosis: how to identify patients with FH for diagnosis and referral. Prim Care Cardiovasc Journal. 7. 1. pp31-35

Thompson, G. and Seed,  M (2014)  The management of familial hypercholesterolaemia. Prim Care Cardiovasc Journal.  7 pp89-91

Humphries, S.  and Futema, M.  (2015) What's new in FH genetics? Prim Care Cardiovasc Journal. 1. 1. Epublication online

Green, P., Qureshi, N (2017) The role of primary care in patients with FH. PCCJ. Online publication.

Wald, D., Bestwick, M. et al (2016) Child parent familial hypercholesterolaemia screening in primary care.  New England Journal of Medicine. 375. pp1628-1637

France, M., Rees, A., Datta, D et al (2016) HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.  Atherosclerosis.  Available at:

Familial hypercholesterolaemia: Including pregnancy, paediatrics and young people

Graham DF, Raal FJ (2021) Management of familial hypercholesterolemia in pregnancy. Curr Opin Lipidol. 1;32(6):370-377. 

Ingoe L, Potter A, et al (2021) Improving the identification of patients with a genetic diagnosis of familial hypercholesterolaemia in primary care: A strategy to achieve the NHS long term plan. Atherosclerosis. 325:38-45. Epub 2021 Apr 2.

Martin AC, Hooper AJ, et al (2021). Pilot study of universal screening of children and child-parent cascade testing for familial hypercholesterolaemia in Australia. J Paediatr Child Health. doi: 10.1111/jpc.15700. Epub ahead of print.

Priestley-Barnham, L. et al (2019) Diagnosis and management of children and young people with Familial Hypercholesterolaemia.  British Journal of Cardiac Nursing.  14. 1. pp22-30.  

Vuorio, A., Kuoppala, J., Kovanen, P.T., Humphries, S., Tonstad, S., Weigman, A et al (2014). Statins for children with Familial Hypercholesterolaemia. Cochrane Database of Systematic Review. 7. Full review available

Lipoprotein (a) 

2022, Volume 29, Supplement 1: Lipoprotein(a) – a perspective on its role in cardiovascular and calcific aortic valve disease. The British Journal of Cardiology. Series. 

Alberico L. Catapano, Magdalena Daccord, Elaine Damato, Steve E. Humphries, R. Dermot G. Neely, Børge G. Nordestgaard, Michele Pistollato, Elisabeth Steinhagen-Thiessen. How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)? Atherosclerosis, 2022

Burgess, S., Ference, B et al (2018) Association of LPA variants with risk of coronary disease and the implications for Lipoprotein (a) lowering therapies: A mendelian randomization analysis.  JAMA Cardiology. 3. 7. pp 619-672.  Full review available

O'Donoghue, M. et al (2019) Lipoprotein (a), PCSK9 inhibition and Cardiovascular Risk: Insights from the FOURIER Trial.  Circulation.  Vol 139, No 12. pp1483-1492.  Abstract available here

Pare, G et al (2019) Lipoprotein (a) Levels and the Risk of Myocardial Infarction among 7 Ethnic Groups.  Circulation. Vol 138. No 12. pp1472-1482.  Abstract available here

Thanassoulis, G. (2019) Editorial.  Screening for High Lipoprotein (a).  The Time is Now.  Circulation. Vol 139. pp1493-1496.  Full editorial available here

Statins and other treatments

Khatib R, Khan M, Barrowcliff A, et al. Innovative, centralised, multidisciplinary medicines optimisation clinic for PCSK9 inhibitors. Open Heart 2022;9:e001931.  doi: 10.1136/openhrt-2021-001931

Khatib, R. Neil, A. et al (2021) Perceptions of injectable therapies with cardiovascular benefit: an ACNAP survey of healthcare professionals to explore facilitators and barriers. European Journal of Cardiovascular Nursing, zvab106. 

The CTT Collaborists (2019) Efficacy and safety of statin therapy in older people: a meta analysis of individual participant data from 28 randomised controlled trials.  The Lancet. Vol 393, issue 10170. pp 407-415.  Available at: Download full paper

Mach, F. Ray, K. et al (2018) Adverse effects of statin therapy: perception vs the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract.  European Heart Journal 0. 1-18. Available at:

 Newman, C., Preiss, D et al (2018) Statin Safety and Associated Adverse Events:  A Scientific Statement From the American Heart Association.  (Arterioscler Thromb Vasc Biol. 2018;38:e00-e00 Available at:

Baigent, C., Landray, M, et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.  The Lancet. 377. 9784. Pp2181-2192. Available online:

Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010. vol 376, no 9753. 1670-1680

Cholesterol Treatment Trialists (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease.  Meta analysis of individual data from 27 randomised trials. Lancet 2012. Aug 11, 380 (9841) 581-590: 

Cannon, C., Blazing, M., et al (2015) Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine. 372. pp2387-2397. Available at:

Collins, R., Reith, C et al (2016) Interpretation of the evidence for the efficacy and safety of statin therapy.  Lancet. 388, 10059. pp2532-2561.  Available at:

Finegold JA, Manisty CH, et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomised placebo controlled trials to aid individual patient choice.  European Journal of Preventative Cardiology. 2014, 21: 464  (abstract only)

Ridker, P., Danielson, E., et al (2008)  JUPITER STUDY: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine. 359. Pp2195-2207.  Available at:

Thompson G (2008) The Cholesterol Controversy. Royal Society of Medicine Press Ltd, London


Sacks. F. , Lichenstein, A et al (2017) Dietary fats and cardiovascular disease, a presidential advisory from the American Heart Association.  Circulation.  136.   ppe1-e23. Available at Circulation online

Estruch, R., Ros, E et al (2013) Primary prevention of cardiovascular disease with a Mediterranean diet. (PREDIMED)  The New England Journal of Medicine.  368. 14. Pp. 1279-90

Mensink RP (2016) Effects of saturated fatty acids on serum lipids and lipoproteins: a systematic review and regression analysis. World Health Organisation

European Food safety Authority (EFSA) 2010 Scientific Opinion on Dietary Reference Values for Fats.  EFSA Journal 2010; 8(3):1461 [107 pp.]. 

Scientific Advisory Committee on Nutrition (2015) Carbohydrates and Health. Available online:

Lipoprotein apheresis

Pottle A., Thompson, G., Barbir, B., Bayly, G., Cegla, J., Cramb, R., Dawson, T et al (2019) Lipoprotein apheresis efficacy, challenges and outcomes: a descriptive analysis from the UK Lipoprotein Apheresis Registry. 1989-2017.  Atherosclerosis: 290. 44-51

Thompson GR, HEART UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis (2008) Atherosclerosis: 198; 247-255. (Abstract only)

 Thompson GR, Barbir M, Davies D et al. Efficiency criteria and cholesterol targets for LDL apheresis. (2010) Atherosclerosis: 208; (Abstract only)

CVD risk

Joint British Societies for the Prevention of Cardiovascular Disease (2014) Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3)  Heart 100. pp. 1-67.  Available at:

National Institute for Health and Care Excellence (2014) Cardiovascular disease: risk assessment and reduction, including lipid modification.  Available at:

Scottish Intercollegiate Guidelines Network (SIGN) Risk estimation and the prevention of cardiovascular disease. 

Public Health England (2014) Adult obesity and type 2 diabetes.  Available online :